Improvement of Stability and Anticancer Activity of ChlorambuciI-Tetrapeptide Conjugate Vesicles  

作　　者：Wei Zhang Wenjun Zhu Ruiyu He Shuo Fang Yemin Zhang Chen Yao Muhammad Ismail Xinsong Li 

机构地区：[1]School of Chemistry and Chemical Engineering, Southeast University, Nanjing, Jiangsu 210096, China

出　　处：《Chinese Journal of Chemistry》2016年第6期609-616,共8页中国化学（英文版）

摘　　要：Chlorambucil is a classic nitrogen mustard drug that has been used in the treatment of cancers. It may induce neutropenia, thrombocytopenia and other side effects because of its short lifetime and off-target effect. In this report, chlorambucil-tetrapeptide （AAAK, A3K） conjugate vesicles were developed to improve the stability and bioactivity of chlorambucil. First of all, chlorambucil-A3K conjugate was synthesized by solid phase synthesis strategy. Sec- ondly, the chlorambucil-A3K conjugate was assembled and characterized by critical aggregation concentration, cir- cular dichroism, dynamic light scattering and transmission electron microscopy. The results indicated that the chlo- rambucil-A3K conjugate can be assembled to form spherical vesicles with an average diameter of 390.5 nm, and high drug loading about 47.1% is reached. Surprisingly, the preliminary biological evaluation of the chlorambu- cil-A3K conjugate vesicles revealed the best in vitro anticancer activity against HeLa, HepG-2 and MCF-7 cell lines compared with chlorambucil and chlorambucil-A3K conjugate free drugs. Furthermore, conjugate vesicles showed excellent in vivo antitumoral activity. It can be partly attributed to their vesicular structure which isolates chloram- bucil active moiety from aqueous solution to retard degradation before killing cancer cells. Therefore, chlorambu- cil-peptide （A3K） conjugate vesicles may be an alternative delivery system of chlorambucil.Chlorambucil is a classic nitrogen mustard drug that has been used in the treatment of cancers. It may induce neutropenia, thrombocytopenia and other side effects because of its short lifetime and off-target effect. In this report, chlorambucil-tetrapeptide （AAAK, A3K） conjugate vesicles were developed to improve the stability and bioactivity of chlorambucil. First of all, chlorambucil-A3K conjugate was synthesized by solid phase synthesis strategy. Sec- ondly, the chlorambucil-A3K conjugate was assembled and characterized by critical aggregation concentration, cir- cular dichroism, dynamic light scattering and transmission electron microscopy. The results indicated that the chlo- rambucil-A3K conjugate can be assembled to form spherical vesicles with an average diameter of 390.5 nm, and high drug loading about 47.1% is reached. Surprisingly, the preliminary biological evaluation of the chlorambu- cil-A3K conjugate vesicles revealed the best in vitro anticancer activity against HeLa, HepG-2 and MCF-7 cell lines compared with chlorambucil and chlorambucil-A3K conjugate free drugs. Furthermore, conjugate vesicles showed excellent in vivo antitumoral activity. It can be partly attributed to their vesicular structure which isolates chloram- bucil active moiety from aqueous solution to retard degradation before killing cancer cells. Therefore, chlorambu- cil-peptide （A3K） conjugate vesicles may be an alternative delivery system of chlorambucil.

关 键 词：chlorambucil-tetrapeptide conjugate SELF-ASSEMBLY vesicles anticancer activity 

分 类 号：O152.1[理学—数学] TQ463.5[理学—基础数学]